Literature DB >> 19555677

Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain.

Nirmal S Bhide1, Jack W Lipton, Jacobi I Cunningham, Bryan K Yamamoto, Gary A Gudelsky.   

Abstract

Repeated exposure to sub-lethal insults has been reported to result in neuroprotection against a subsequent deleterious insult. The purpose of this study was to evaluate whether repeated exposure (preconditioning) to a non-5-HT depleting dose of MDMA in adult rats provides neuroprotection against subsequent MDMA-induced 5-HT depletion. Treatment of rats with MDMA (10 mg/kg, ip every 2 h for 4 injections) resulted in a 50-65% depletion of 5-HT in the striatum, hippocampus and cortex, and these depletions were significantly attenuated in rats that received a preconditioning regimen of MDMA (10 mg/kg, ip daily for 4 days). The 5-HT depleting regimen of MDMA also resulted in a 40-80% reduction in 5-HT transporter immunoreactivity (SERT(ir)), and the reduction in SERT(ir) also was completely attenuated in MDMA-preconditioned animals. Preconditioning with MDMA (10 mg/kg, ip) daily for 4 days provided neuroprotection against methamphetamine-induced 5-HT depletion, but not dopamine depletion, in the striatum. Additional studies were conducted to exclude the possibility that alterations in MDMA pharmacokinetics or MDMA-induced hyperthermia in rats previously exposed to MDMA contribute towards neuroprotection. During the administration of the 5-HT depleting regimen of MDMA, there was no difference in the extracellular concentration of the drug in the striatum of rats that had received 4 prior, daily injections of vehicle or MDMA. Moreover, there was no difference in the hyperthermic response to the 5-HT depleting regimen of MDMA in rats that had earlier received 4 daily injections of vehicle or MDMA. Furthermore, hyperthermia induced by MDMA during preconditioning appears not to contribute towards neuroprotection, inasmuch as preconditioning with MDMA at a low ambient temperature at which hyperthermia was absent did not alter the neuroprotection provided by the preconditioning regimen. Thus, prior exposure to MDMA affords protection against the long-term depletion of brain 5-HT produced by subsequent MDMA administration. The mechanisms underlying preconditioning-induced neuroprotection for MDMA remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555677      PMCID: PMC2754382          DOI: 10.1016/j.brainres.2009.06.042

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

1.  'Ischemic tolerance' phenomenon found in the brain.

Authors:  K Kitagawa; M Matsumoto; M Tagaya; R Hata; H Ueda; M Niinobe; N Handa; R Fukunaga; K Kimura; K Mikoshiba
Journal:  Brain Res       Date:  1990-09-24       Impact factor: 3.252

Review 2.  Cerebral ischemic preconditioning. An experimental phenomenon or a clinical important entity of stroke prevention?

Authors:  B Schaller; R Graf
Journal:  J Neurol       Date:  2002-11       Impact factor: 4.849

3.  Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.

Authors:  M Shankaran; B K Yamamoto; G A Gudelsky
Journal:  Eur J Pharmacol       Date:  1999-12-03       Impact factor: 4.432

4.  The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity.

Authors:  Kamisha L Johnson-Davis; Annette E Fleckenstein; Diana G Wilkins
Journal:  Eur J Pharmacol       Date:  2003-12-15       Impact factor: 4.432

5.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.

Authors:  E O'Hearn; G Battaglia; E B De Souza; M J Kuhar; M E Molliver
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

6.  (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.

Authors:  G A Ricaurte; L S Forno; M A Wilson; L E DeLanney; I Irwin; M E Molliver; J W Langston
Journal:  JAMA       Date:  1988-07-01       Impact factor: 56.272

7.  Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.

Authors:  M H Baumann; R D Clark; F H Franken; J J Rutter; R B Rothman
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

8.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

9.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.

Authors:  C J Schmidt
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

10.  Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.

Authors:  Douglas C Jones; Serrine S Lau; Terrence J Monks
Journal:  J Pharmacol Exp Ther       Date:  2004-05-28       Impact factor: 4.030

View more
  8 in total

1.  (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

Authors:  Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

2.  Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1β mRNA expression in the hypothalamus.

Authors:  Michael J Seminerio; Matthew J Robson; Christopher R McCurdy; Rae R Matsumoto
Journal:  Eur J Pharmacol       Date:  2012-07-20       Impact factor: 4.432

3.  MDMA self-administration fails to alter the behavioral response to 5-HT(1A) and 5-HT(1B) agonists.

Authors:  Dane Aronsen; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2016-02-09       Impact factor: 4.530

4.  Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake.

Authors:  Courtney Huff; Nirmal Bhide; Allen Schroering; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Brain Res Bull       Date:  2013-01-12       Impact factor: 4.077

5.  Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA.

Authors:  Andrea Mayado; Elisa Torres; Maria D Gutierrez-Lopez; Maria I Colado; Esther O'Shea
Journal:  J Neuroinflammation       Date:  2011-11-24       Impact factor: 8.322

Review 6.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21

7.  New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain.

Authors:  Ibrahim M Shokry; John J Callanan; John Sousa; Rui Tao
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

8.  Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats.

Authors:  Ibrahim M Shokry; Connor J Shields; John J Callanan; Zhiyuan Ma; Rui Tao
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-05       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.